154278-84-9

Upstream product

• 121686-87-1 (2R,3S)-N-benzyl-3-hydroxy-2-hydroxymethylpyrrolidine 
• 103201-79-2 (3R,7aS)-3-phenyl-tetrahydro-pyrrolo[1,2-c]oxazol-5-one 
• 1049770-22-0 (2R,3S)-2-(benzyloxymethyl)-3-(tert-butoxy)-1-hydroxypyrrolidine 
• 27451-36-1 (RS)-3-hydroxypent-4-enenitrile 
• 1049770-27-5 (S)-2-(benzyloxymethyl)-3-(tert-butoxy)-3,4-dihydro-2H-pyrrole 1-oxide 
• 1049770-33-3 (2S,3S)-2-(benzyloxymethyl)-3-(tert-butoxy)-1-hydroxypyrrolidine 
• 123287-88-7 (2S,3R)-tert-butyl 3-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 130193-02-1 (2R,3R)-1-(tert-Butoxycarbonyl)-2.(hydroxymethyl)-3-hydroxypyrrolidine 
• 118449-01-7 (2R,3S)-3-hydroxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 4298-08-2 trans-3-hydroxy-L-proline 
• 156129-72-5 (2R,3S)-tert-butyl 3-hydroxy-2-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 187039-57-2 (2S,3S)-1-(tert-butoxycarbonyl)-3-hydroxypyrrolidine-2-carboxylic acid 
• 1214733-75-1 (7S,7aS)-7-hydroxytetrahydro-1H-pyrrolo[1,2-c]oxazol-3-one 
• 138515-34-1 (2S,3S)-1-(Benzyloxycarbonyl)-3-hydroxy-2-(hydroxymethyl)pyrrolidine 

Relevant academic research and scientific papers

Protecting-group-free synthesis of 2-deoxy-aza-sugars

The protecting-group-free asymmetric synthesis of 1,2,4-trideoxy-1,4-imino- L-xylitol is readily achieved in five steps from 2-deoxy-D-ribose and with an overall yield of 48%. Key in this synthesis is the application of our recently developed Vasella-redu

7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF

The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.

SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY

The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof.

DIFLUOROPYRROLIDINES AS OREXIN RECEPTOR MODULATORS

The present application relates to certain difluoropyrrolidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.

METHODS FOR THE PREPARATION OF ALKENYLAMINES, CYCLIC CARBAMATES OR DITHIOCARBAMATES, AND AMINOALCOHOLS OR AMINOTHIOLS

A method for preparing an alkenylamine, or a salt, solvate or hydrate thereof, is disclosed. The method comprises reacting a alogen-substituted cyclic acetal or a derivative thereof under particular conditions to provide the alkenylamine, which may be optionally converted into a salt, solvate or hydrate thereof. A method for preparing a cyclic carbamate or cyclic dithiocarbamate, or a salt, solvate or hydrate thereof, is also disclosed. The method comprises reacting an alkenylamine under particular conditions to provide the cyclic carbamate or cyclic dithiocarbamate, which may be optionally converted into a salt, solvate or hydrate thereof. A method for preparing a 1,2-aminoalcohol or 1,2-aminothiol, or a salt, solvate or hydrate thereof, is also disclosed. The method comprises forming a cyclic carbamate or cyclic dithiocarbamate from an alkenylamine, and deprotecting the cyclic carbamate or cyclic dithiocarbamate to provide the 1,2-aminoalcohol or 1,2-aminothiol, which may optionally be converted into a salt, solvate or hydrate thereof.

AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE

The invention relates to azabenzofuranyl compounds of Formula (I) with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzofuranyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

Nucleophilic additions to cyclic nitrones en route to iminocyclitols - Total syntheses of DMDP, 6-deoxy-DMDP, DAB-1, CYB-3, nectrisine, and radicamine B

Highly diastereoselective nucleophilic additions to cyclic nitrones derived from L-malic acid and D-arabinose have been used for the construction of enantiomerically pure polyhydroxylated pyrrolidines. The synthetic strategy adopted was based on an oxidat

GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS

A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein.

A new stereospecific synthesis of 1,2,4-Trideoxy-1,4-imino-D-erythro-pentitol

1,2,4-Trideoxy-1,4-imino-D-erythro-pentitol [(2R,3S)-3-hydroxy-2-hydroxymethylpyrrolidine] (4) was synthesised from 2,5-di-O-tosyl-D-ribono-1,4-lactone in 42 % overall yield. The key steps were deoxygenation at C-2 and a stereospecific inversion of the co

Chromium(II) chloride-mediated coupling reactions of Garner aldehyde with allyl bromides: Facile asymmetric synthesis of (2R,3S)-3-hydroxy-2-hydroxymethylpyrrolidine

Chromium(II) chloride-mediated coupling reactions of 1,1-dimethylethyl (S)- and (R)-4-formyl-2,2-dimethyloxazolidine-3-carboxylates [(S)- and (R)-Garner aldehydes] (1a,b) with allyl bromides 2a-c proceeded with moderate to good stereoselectivity to give t